









市場行情
/
股票
/
nasdaq-atha
/

Athira Pharma Inc

ATHA

6.970USD

+0.250+3.72%

收盤 12/19, 16:00（美東）報價延遲15分鐘

27.49M總市值

虧損本益比TTM



Athira Pharma Inc

6.970

+0.250+3.72%

概覽公司財務分析

概覽

公司

財務

分析

關於 Athira Pharma Inc 公司

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.

Athira Pharma Inc簡介



公司代碼ATHA

公司名稱Athira Pharma Inc

上市日期Sep 18, 2020

CEOLitton (Mark James)

員工數量26

證券類型Ordinary Share

年結日Sep 18

公司地址18706 North Creek Parkway, Suite 104

城市BOTHELL

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編98011

電話14256208501

網址https://www.athira.com/

公司代碼ATHA

上市日期Sep 18, 2020

CEOLitton (Mark James)

Athira Pharma Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Mark James Litton, Ph.D.

President, Chief Executive Officer, Director

34.55K

-6.78%

Dr. Kevin Church, Ph.D.

Chief Scientific Officer

16.89K

-4.81%

Mr. Mark Worthington

Chief Compliance Officer, General Counsel, Company Secretary

11.19K

-7.08%

Mr. Robert Renninger

Senior Vice President - Finance, Accounting

10.92K

-2.59%

Ms. Kelly A. Romano

Independent Chairwoman of the Board

8.07K

-23.06%

Dr. Javier San Martin, M.D.

Chief Medical Officer

7.17K

-13.14%

Mr. Grant E. Pickering

Independent Director

2.58K

James A. Johnson ,

Independent Director

500.00

Ms. Barbara Kosacz, J.D.

Independent Director

Ms. Julie Rathbun

Investor Relations

名稱

名稱/職務

職務

持股

持股變動

Dr. Mark James Litton, Ph.D.

President, Chief Executive Officer, Director

34.55K

-6.78%

Dr. Kevin Church, Ph.D.

Chief Scientific Officer

16.89K

-4.81%

Mr. Mark Worthington

Chief Compliance Officer, General Counsel, Company Secretary

11.19K

-7.08%

Mr. Robert Renninger

Senior Vice President - Finance, Accounting

10.92K

-2.59%

Ms. Kelly A. Romano

Independent Chairwoman of the Board

8.07K

-23.06%

Dr. Javier San Martin, M.D.

Chief Medical Officer

7.17K

-13.14%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月20日週六

持股股東

股東類型

持股股東

佔比

Perceptive Advisors LLC

13.70%

Simplify Asset Management Inc

7.57%

Baselake Management, LLC

5.63%

Nemean Asset Management, LLC

4.09%

The Vanguard Group, Inc.

3.90%

其他

65.11%

持股股東

佔比

Perceptive Advisors LLC

13.70%

Simplify Asset Management Inc

7.57%

Baselake Management, LLC

5.63%

Nemean Asset Management, LLC

4.09%

The Vanguard Group, Inc.

3.90%

其他

65.11%

股東類型

持股股東

佔比

Private Equity

13.96%

Investment Advisor

13.62%

Corporation

9.73%

Hedge Fund

4.09%

Venture Capital

3.79%

Individual Investor

3.63%

Investment Advisor/Hedge Fund

2.20%

Family Office

0.98%

Research Firm

0.83%

其他

47.17%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

111

1.69M

59.67%

+2.61K

2025Q3

123

1.85M

67.42%

-29.98K

2025Q2

137

1.88M

68.23%

-792.00

2025Q1

169

1.88M

71.62%

-912.05K

2024Q4

181

1.93M

77.37%

-30.53K

2024Q3

198

1.93M

80.55%

-610.31K

2024Q2

215

2.54M

81.59%

+49.57K

2024Q1

233

2.49M

97.31%

-1.23M

2023Q4

240

2.51M

94.17%

+48.15K

2023Q3

248

2.46M

95.12%

-62.03K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Perceptive Advisors LLC

540.30K

13.7%

Jun 30, 2025

Simplify Asset Management Inc

149.28K

3.79%

Jun 30, 2025

Nemean Asset Management, LLC

199.47K

5.06%

+199.47K

Apr 14, 2025

The Vanguard Group, Inc.

153.79K

3.9%

Jun 30, 2025

Tang Capital Management, LLC

60.00K

1.52%

Jun 30, 2025

Renaissance Technologies LLC

24.10K

0.61%

+2.20K

+10.05%

Jun 30, 2025

Acadian Asset Management LLC

40.55K

1.03%

-2.31K

-5.38%

Jun 30, 2025

Pathstone

37.22K

0.94%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

37.24K

0.94%

-7.40K

-16.58%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Propel Opportunities ETF

0.92%

iShares Neuroscience and Healthcare ETF

Avantis US Small Cap Equity ETF

iShares US Small-Cap Equity Factor ETF

iShares Micro-Cap ETF

Dimensional US Core Equity 1 ETF

DFA Dimensional US Sustainability Core 1 ETF

Simplify Propel Opportunities ETF

佔比0.92%

iShares Neuroscience and Healthcare ETF

佔比0%

Avantis US Small Cap Equity ETF

佔比0%

iShares US Small-Cap Equity Factor ETF

佔比0%

iShares Micro-Cap ETF

佔比0%

Dimensional US Core Equity 1 ETF

佔比0%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Sep 11, 2025

Merger

10→1

公告日期

類型

比率

Sep 11, 2025

Merger

10→1

常見問題

Athira Pharma Inc的前五大股東是誰？



Athira Pharma Inc的前五大股東如下：
Perceptive Advisors LLC
持有股份：540.30K
佔總股份比例：13.70%。
Simplify Asset Management Inc
持有股份：149.28K
佔總股份比例：3.79%。
Nemean Asset Management, LLC
持有股份：199.47K
佔總股份比例：5.06%。
The Vanguard Group, Inc.
持有股份：153.79K
佔總股份比例：3.90%。
Tang Capital Management, LLC
持有股份：60.00K
佔總股份比例：1.52%。